Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06858878 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
A Phase 3 study of Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 1,105
- Enrollment target
- 20
- Study locations
NCT06858878: Active Phase 3 study of Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, sponsored by Amgen.
NCT06858878 is a Phase 3 study of Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight that is active but no longer recruiting, run by Amgen. The registered enrollment target is 1,105 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06858878, a Phase 3 study of Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,105 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart cafraglutide
Study Locations (20)
California
- San Fernando Valley Health Institute - Canoga Park
- Core Healthcare Group - Cerritos
- Velocity Clinical Research Chula Vista - Chula Vista
- Headlands Research California - Escondido
- Paradigm Clinical Research - Modesto
- Flourish Research - Northridge
- University of California Irvine - Orange
- Empire Clinical Research - Pomona
- Infinity Clinical Trials - San Diego
Florida
- Indago Research and Health Center - Hialeah
- Optimus U Corporation - Miami
- New Horizon Research Center - Miami
- San Marcus Research Clinic Inc - Miami Lakes
- Florida Institute for Clinical Research - Orlando
- Encore Medical Research of Weston LLC - Weston
Arizona
- Gilbert Center for Family Medicine - Gilbert
- Desert Clinical Research - Mesa
- Avacare Foothills Research Center - Phoenix
Alabama
- Alliance for Multispecialty Research Mobile - Mobile
Connecticut
- Greenwich Clinical Trials - Riverside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,105 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2027-04-16 |
| Phase | Phase 3 |
What the registry record for NCT06858878 still lists
NCT06858878 is an interventional study that assigns participants to a tested intervention. Its 1,105 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06858878 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06858878 about?
NCT06858878 is a clinical study titled "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight". The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
What is the current status of trial NCT06858878?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,105 participants. The study started on 2025-03-17. Estimated completion is 2027-04-16.
What conditions does trial NCT06858878 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight.
What interventions are being tested in trial NCT06858878?
The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).
Who is sponsoring clinical trial NCT06858878?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06858878 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06858878's enrollment target sits among peer trials
1,105 251st of 2000 higher than 1,750 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI